FDA-approved1,2Evidence: Large human trialsNot a single peptideBrain, nerves and sleep · Inflammation and immune

Glatiramer acetate1,2

Also called Copaxone1,2

Not a single peptide: a mixture often looked up alongside peptides.

Key takeaway

Glatiramer acetate is not a single peptide: it is a mixture of synthetic polypeptides built from four amino acids, glutamic acid, alanine, tyrosine and lysine, in fixed proportions. It is the active ingredient in Copaxone.1,3 FDA approved Copaxone in 1996, and its label covers relapsing forms of multiple sclerosis in adults.1,2 In the largest trial in the label, 1,404 people with relapsing-remitting multiple sclerosis had 34% fewer relapses over a year than on placebo. The label carries a boxed warning about life-threatening and fatal anaphylaxis.1

Glatiramer acetate at a glance

Substance typeNot a single peptide. The Copaxone label states that glatiramer acetate consists of the acetate salts of synthetic polypeptides made from four amino acids, and FDA’s substance registry records it as a polymer.1,3
What it isAcetate salts of synthetic polypeptides made of L-glutamic acid, L-alanine, L-tyrosine and L-lysine, with an average molecular weight of 5,000 to 9,000 daltons, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Copaxone, NDA 020622, with an original approval date of December 20, 1996. The label has a boxed warning about anaphylaxis.1,2
Human evidenceFive placebo-controlled trials in relapsing multiple sclerosis described in the label, the largest in 1,404 people.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is glatiramer acetate?

The label states that glatiramer acetate consists of the acetate salts of synthetic polypeptides containing four naturally occurring amino acids, L-glutamic acid, L-alanine, L-tyrosine and L-lysine, in average molar fractions of 0.141, 0.427, 0.095 and 0.338.1

FDA’s substance registry records it as a polymer, also called copolymer-1, rather than as one defined molecule.3

In the United States it is the active ingredient of Copaxone, NDA 020622, according to Drugs@FDA.2

How does glatiramer acetate work?

The label states that how it works in multiple sclerosis is not fully understood, but that it is thought to act by modifying immune processes believed to drive the disease.1

What do human studies show?

In Study 5, 1,404 people with relapsing-remitting multiple sclerosis were randomized to glatiramer acetate or placebo for 12 months; the relative risk of confirmed relapses was 34% lower with glatiramer acetate, according to the label.1

In Study 2, 251 people were followed for two years; the mean relapse rate was 1.19 with glatiramer acetate and 1.68 with placebo, a difference with a p-value of 0.055. Study 4, in 239 people, found fewer MRI lesions over nine months.1

What the evidence base contains

  • Large randomized human trial Study 5: a double-blind, placebo-controlled, multinational trial in which 1,404 people with relapsing-remitting multiple sclerosis were randomized; confirmed relapses over 12 months were 34% lower with glatiramer acetate, described in the label.1
  • Controlled human trial Four earlier placebo-controlled trials in 50, 251, 481 and 239 people, with results on relapse rates and MRI lesions, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is glatiramer acetate FDA-approved?

Yes. Drugs@FDA lists Copaxone, NDA 020622, with an original approval date of December 20, 1996.2

The Copaxone label cited here (DailyMed SPL version 36, published June 26, 2026) states that it is indicated for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1

The label carries a boxed warning that life-threatening and fatal anaphylaxis has been reported, at any time from the first exposure to years after starting, and that it must not be used by people with a history of hypersensitivity reactions to it, including anaphylaxis.1

Timeline

  1. FDA approves Copaxone, NDA 020622, according to Drugs@FDA.2
  2. DailyMed publishes version 36 of the Copaxone label, the version cited here.1

What is still unknown?

Exactly how it works in multiple sclerosis, which the label states is not fully understood.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Glatiramer acetate: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Glatiramer acetate are a bounded selection, not every registration or paper about Glatiramer acetate. For the years before Glatiramer acetate was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Glatiramer acetate as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Glatiramer acetate in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Copaxone for relapsing multiple sclerosis. The label describes five placebo-controlled trials; in the largest, 1,404 people had 34% fewer relapses. The label carries a boxed warning about anaphylaxis.↗↗

Status sources checked through November 16, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Glatiramer acetate?

FDA-approved as Copaxone for relapsing multiple sclerosis. The label describes five placebo-controlled trials; in the largest, 1,404 people had 34% fewer relapses. The label carries a boxed warning about anaphylaxis.↗↗

The cited status sources were checked through November 16, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
16
Drugs@FDA applications
11

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 16, 2026

ClinicalTrials.gov record NCT05344469↗Added to PeptideScanner November 17, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Glatiramer acetate?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

65Selected dated records
68Connected citations
16Populated source years1996–2026
3/4Record lanes present

Registered human studies

Trial composition

24 of 26 selected trial records include at least one phase value; 26 of 26 include a status value in the retained structured contract.

PhasesPhase 3 9Phase 4 8Phase 2 6Not applicable 1
Status at observationCompleted 25Recruiting 1

A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 25Review 14Research Support, Non-U.S. Gov't 9Randomized Controlled Trial 6Clinical Trial, Phase III 3Multicenter Study 3Systematic Review 3Meta-Analysis 2Research Support, N.I.H., Extramural 2Clinical Trial, Phase II 1Controlled Clinical Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
11
FDA Federal Register documents
3
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
65

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 65 dated records

Research hub

Explore the Glatiramer acetate evidence record

Open all 65 records →
65Dated records
3Evidence types
65Cited public sources
16Source years

Change ledger

Recently changed for Glatiramer acetate

Open all 65 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT05344469

PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 17, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Glatiramer acetate

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026 02 18
  2. Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair.Pharmacological reviews · 2024 10 16
  3. Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.Cells · 2022 05 07
Explore all selected literature →
ClinicalTrials.gov26

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05344469Registry update November 16, 2026 · current at observation
  2. NCT03193866Registry update April 20, 2025 · completed at observation
  3. NCT01067521Registry update December 9, 2021 · completed at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA11

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA213382Full FDA chronology · original submission status AP 2026-02-11
  2. ANDA214022Full FDA chronology · original submission status AP 2026-02-11
  3. ANDA214741Full FDA chronology · original submission status AP 2025-12-31
  4. ANDA208468Full FDA chronology · original submission status AP 2025-05-07
  5. ANDA203857Full FDA chronology · original submission status AP 2024-09-25
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Glatiramer acetate →

Evidence types

Coverage by source year

Selected records span December 20, 1996 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3
Dated updates connected to this profile · 65

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT05344469↗

    PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

  2. Literature metadata

    Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.↗

    PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.↗

    PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair.↗

    PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Randomized study combining interferon and glatiramer acetate in multiple sclerosis.↗

    PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Drugs@FDA application ANDA213382↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213382 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗

  7. Regulatory

    Drugs@FDA application ANDA214022↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 214022 with status AP dated 2026-02-11, and names glatiramer acetate among the application record's active ingredients.↗

  8. Regulatory

    Drugs@FDA application ANDA214741↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 214741 with status AP dated 2025-12-31, and names glatiramer acetate among the application record's active ingredients.↗

  9. Literature metadata

    Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.↗

    PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.↗

    PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Regulatory

    Drugs@FDA application ANDA208468↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 208468 with status AP dated 2025-05-07, and names glatiramer acetate among the application record's active ingredients.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT03193866↗

    PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    COPAXONE (glatiramer acetate injection) · SPL version 36 · published 2026-06-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: COPAXONE (glatiramer acetate), NDA 020622 · original approval December 20, 1996 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  3. 3
    Glatiramer acetate substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026